Skip to content
Screener

Relmada Therapeutics, Inc. RLMD Q3 2025 earnings

Reported November 13, 2025 · After market close

EPS-$0.30Miss by $0.26
EPS estimate-$0.04

Next report

Nov 12, 2026 (in 2 months)
EPS estimate-$0.14

Financials

Q3 2025

Income statement

See full
Operating income-$10.3M+55.1%
Net income-$10.1M+53.6%
EPS (diluted)-$0.30+58.3%

Balance sheet

See full
Cash & equivalents$1.4M-6.7%
Total equity$9.5M-80.1%
Total assets$14.9M-73.3%

Cash flow

See full
Operating cash flow-$6.7M+59.6%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$66.72M-31.8%

Returns & leverage

See full
Return on equity-196.8%+433pp
Current ratio2.9×-4.0×

FAQ

When did Relmada Therapeutics, Inc. report Q3 2025 earnings?
Relmada Therapeutics, Inc. (RLMD) reported Q3 2025 earnings on November 13, 2025 after market close.
What were Relmada Therapeutics, Inc.'s Q3 2025 revenue and EPS?
Relmada Therapeutics, Inc. reported eps of $-0.30 for Q3 2025.
Did Relmada Therapeutics, Inc. beat estimates in Q3 2025?
EPS missed the consensus estimate of $-0.04 by $0.26.
How did Relmada Therapeutics, Inc.'s Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, eps grew 58.3% from $-0.72.
Where can I find Relmada Therapeutics, Inc.'s Q3 2025 SEC filings?
You can read the 8-K earnings release (0001213900-25-110088) and the 10-Q periodic report (0001213900-25-109983) directly on SEC EDGAR. The filing index links above go to sec.gov.